Pharma Marketletter

View more issues:

Articles in September, 2003 issue of Pharma Marketletter

• US MCO pharmacy warns Congress against Rx benefit over-regulation.
• 11th-hour agreement gives WTO drug access deal to take to Cancun.
• Tokyo pharma stocks - week to Sept 8.
• Generic Paxil launch hits GSK's shares.
• Cancer Research UK slams Brussels red tape for "strangling" research.
• Novo Nordisk invests 130 million euros in insulin cartridge facility.
• Positive Phase III data for Aventis/Genta's Genasense in melanoma.
• Prana Biotech raises A$5 million.
• Abbott's humira is cleared in the EU as a therapy for rheumatoid arthritis.
• Promising Ph III data for DOV's bicifadine.
• FDA five-part strategic plan to "protect and advance America's health".
• German health reform "will cost pharma close to 3B euros in 2004," says VFA.
• Stock Commentary - Europe.
• Acambis CEO steps down, despite success; results on track in first half.
• New drugs added to Israel's NHI basket.
• France cuts prices of two top-selling drugs.
• USA, key WTO member states agree drug access deal.
• French health service directorate head fired.
• Coversyl cuts cardiac events in CAD.
• Taiwan biotech grows, "needs overseas links".
• One year into drug production/quality modernization, US FDA unveils new steps.
• Novo Nordisk's DAWN study reveals resistance to insulin therapy.
• New data for UCB Pharma's Keppra.
• Stock Commentary - New York.
• Retail drug sales up 7% in year to June.
• Eisai/Pfizer's Aricept shows significant benefits for dementia caused by stroke.
• UK NICE recommends first-line use of Novartis' Glivec in chronic-phase CML.
• Approval of Xoma/Genentech's Raptiva still on track after backing by FDA panel.
• Chemical Synthesis Services opens new L25 million facility in Northern Ireland.
• Elan losses narrow but revenues plunge 46%.
• ECoJ Opinion backs parallel importers.
• Promising preliminary Phase Ib/II data for Genentech's Lucentis as AMD therapy.
• Pfizer's Viagra faces competion as FDA approves GSK/Bayer's Levitra.
• Sanofi-Synthelabo ups forecast on strong 1st-half, but fears persist over key patent.
• Acambis opens up US window via BPC deal.
• US seniors' Rx cost fears, even with a benefit.
• Resignation of Health Minister puts Hungary's health reform in further chaos.
• US FDA calls on pharma for anti-radiation NDAs.
• Stock Commentary - New York.
• UK NICE: glitazones in type 2 diabetes.
• NIH to look at benefits of soy supplements.
• Shire files key law suit against Barr Labs.
• Stock Commentary - Tokyo.
• Elan finally files report; shares leap as investors breathe a sigh of relief.
• Australian Pharmaceutical Industries' unit sees license suspended.
• UPDATE: Cephalon makes $384M Cima Labs bid, trumps aaiPharma offer.
• J&J's $700M payments from stent dispute.
• UPDATE- Novartis enters omeprazole battlefield in USA; competitors' shares slide.
• US insurance "would cover Rx benefit".
• Stock Commentary - Europe.
• S-P introduces cost cutting measures.
• Pliva on track, but profits hit by currency.
• Orion and Novartis' Stalevo shows benefits in Parkinson's disease.
• Indian pharma's mixed response to WTO Rx access deal, while WHO urges speed.
• Study shows potential of Celgene's Thalomid plus temozolomide for melanoma.
• Govt aims to capitalize on New Zealand's blossoming biotech industry.
• Tokyo pharma stocks - week to Sept 15.
• Logic of in-house drug development vs in-licensing, as assessed by Mercer.
• German PO to direct-mail Rx drugs.
• Celltech beats expectations but new strategy gets luke warm reception from market.
• OTCs can be paid for with pre-tax dollars through FSAs, say IRS, US Treasury.
• European Commissioner presents clinical trials program to African health ministers.
• French drugmakers in pricing conundrum.
• UK consults on future of PPRS, proposes new generics reimbursement/supply scheme.
• UK NICE has "inherent contradiction" over transparency, data confidentiality: WHO.
• Spain's new Rx reference price scheme "will strangle R&D and cut profits up to 25%".
• Cash-strapped Xenova makes L8.5 million bid for rival KS Biomedix.
• UPDATE- Elan pays for further noteholder waivers.
• Encouraging results for AstraZeneca on Exanta and Atacand.
• Biotech steadies itself for re-opening of IPO window; strong 4th qtr expected.
• Recordati to divest pharma chemicals unit by year end; plans European acquisition?
• Farmaindustria says new reference prices will hurt Spanish drug industry.
• Israel saw continuous increase in national expenditure on health in 2002.
• Lilly forecasts sales in Spain to rise 15%.
• South African drug price panel named.
• Tokyo pharma stocks - week to August 25.
• Intercare to boost drug-making arm.
• Japan's Takara moves into drug innovation.
• Stock Commentary - New York.
• Stock Commentary - New York.

• 1
• 2